News Sentiment

EVGN sentiment intelligence

Evogene news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.51 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+19.2% over one week, -12.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

AgPlenus Launches Antifungal Potency Predictor, Expanding ChemPass AI for Ag Capabilities

Market Reaction

Price moving ahead of tone

64/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 19.2% Price confirming higher
Trend fit Trend inactive -12.3% over four weeks
Fair value -85.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 23
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
Market source 7
PR Newswire 5
TradingView 5
The Globe and Mail 2
www.marketscreener.com 2
Investing.com 2
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 22
Earnings 17
Guidance 4
Deals and strategy 3
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
iGrow News Direct company coverage

AgPlenus Launches Antifungal Potency Predictor, Expanding ChemPass AI for Ag Capabilities

AgPlenus, a subsidiary of Evogene Ltd., has introduced its Antifungal Potency Predictor (APP), a machine learning model designed to forecast the antifungal potency of small molecules from their chemical structures. This AI tool expands Evogene's ChemPass AI for Ag™ platform, enab

Tone
Positive 72/100
Event
Guidance
Published
16 Jul 2026 21:42
Source
iGrow News
Stock Titan Direct company coverage

AgPlenus AI Predicts Fungicide Potency Before Synthesis

AgPlenus, a subsidiary of Evogene (NASDAQ: EVGN), has launched its Antifungal Potency Predictor (APP), a new machine learning model designed to forecast the antifungal potency of small molecules directly from their chemical structure. This expansion of the ChemPass AI for Ag™ pla

Tone
Positive 82/100
Event
Guidance
Published
15 Jul 2026 16:41
Source
Stock Titan
PR Newswire Direct company coverage

AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities

AgPlenus, a subsidiary of Evogene, announced the launch of its Antifungal Potency Predictor (APP), a new AI model designed to forecast the antifungal potency of small molecules earlier in the discovery process. This expansion amplifies the capabilities of Evogene's ChemPass AI fo

Tone
Neutral 50/100
Event
Guidance
Published
15 Jul 2026 11:12
Source
PR Newswire
TradingView Direct company coverage

Kfir Silberman Pushes for Board Changes at Evogene with 12.61% Stake

Kfir Silberman, through L.I.A. Pure Capital Ltd., has disclosed a 12.61% stake in Evogene Ltd. and is pushing for significant board changes. He has requested a special shareholder meeting to remove current board members (except Mr. Ofer Haviv), elect his nominees, and approve the

Tone
Negative 39/100
Event
Deals and strategy
Published
10 Jul 2026 13:40
Source
TradingView
Stock Titan Direct company coverage

Evogene (EVGN) investors with 12.61% and 4.13% stakes seek major board changes

Two Evogene Ltd. shareholders, L.I.A. Pure Capital Ltd. (12.61% stake) and Invest Pro Shukai Hon Ltd. (4.13% stake), are pushing for significant changes to Evogene's board of directors. They have formally demanded a special general meeting to remove most current directors, elect

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jul 2026 13:40
Source
Stock Titan
AllSci Direct company coverage

Evogene Partners with Tel Aviv University on AI Drug...

Evogene, a computational chemistry company, is partnering with Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) to accelerate small-molecule drug discovery using Evogene's ChemPass AI platform. This collaboration, facilitated by Ramot, will combine AI-driven desig

Tone
Positive 71/100
Event
Market update
Published
09 Jul 2026 15:09
Source
AllSci
Pharmaceutical Business review - Direct company coverage

Evogene and Tel Aviv University launch drug discovery initiative

Evogene and Tel Aviv University’s Blavatnik Center for Drug Discovery (BCDD) have partnered to accelerate small-molecule drug discovery from Israeli academic research. The collaboration aims to overcome obstacles in early-stage drug development by combining Evogene's AI-based com

Tone
Positive 74/100
Event
Market update
Published
09 Jul 2026 09:41
Source
Pharmaceutical Business review -
Sahm Direct company coverage

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) have announced a joint initiative to accelerate AI-driven small-molecule drug discovery. This collaboration aims to bridge the gap between academic biological insights and viable drug development program

Tone
Positive 74/100
Event
Market update
Published
09 Jul 2026 04:12
Source
Sahm
www.marketscreener.com Direct company coverage

Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

Evogene Ltd. and the Blavatnik Center for Drug Discovery at Tel Aviv University have partnered in a joint initiative to accelerate AI-driven small-molecule drug discovery. This collaboration aims to bridge the gap between academic research and drug candidate development by combin

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 16:40
Source
www.marketscreener.com
BioSpectrum Asia Direct company coverage

Evogene and Tel Aviv University to accelerate AI-driven small-molecule drug discovery

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) have partnered to accelerate AI-driven small-molecule drug discovery. This strategic initiative combines BCDD's experimental infrastructure with Evogene's ChemPass AI™ generative engine to bridge the gap

Tone
Positive 71/100
Event
Market update
Published
08 Jul 2026 13:50
Source
BioSpectrum Asia
Investing.com Direct company coverage

Evogene partners with Tel Aviv University center on drug discovery

Evogene Ltd. is collaborating with Tel Aviv University's Blavatnik Center for Drug Discovery (BCDD) to support small-molecule drug discovery projects from Israeli academic institutions. The partnership will combine Evogene’s ChemPass AI computational chemistry platform with BCDD’

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 11:39
Source
Investing.com
Stock Titan Direct company coverage

Evogene and Tel Aviv University team up to speed small-molecule drug discovery

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery have announced a joint initiative to accelerate AI-driven small-molecule drug discovery. The collaboration will integrate Evogene's ChemPass AI™ platform with BCDD's experimental infrastructure under a Design-M

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 10:39
Source
Stock Titan
The Jerusalem Post Direct company coverage

How Evogene is changing the future for the pharma and agriculture markets

Evogene, a company founded in 2002, is leveraging its AI-driven computational platform, ChemPass AI™, to revolutionize small molecule discovery for pharmaceutical and agricultural markets. By integrating AI, computational chemistry, biology, and data science, Evogene aims to acce

Tone
Positive 91/100
Event
Market update
Published
06 Jul 2026 08:41
Source
The Jerusalem Post
Moomoo Direct company coverage

Evogene | 6-K: Report of foreign private issuer (related to financial reporting)

This article is a 6-K filing by Evogene, which is a report for a foreign private issuer. These filings typically relate to financial reporting and other material information that needs to be disclosed to the SEC. Without the actual document, specific details are unavailable, but

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 23:39
Source
Moomoo
TradingView Direct company coverage

Price to book forward of Evogene Ltd. – NASDAQ:EVGN

This page displays the "Price to book forward" metric for Evogene Ltd. (NASDAQ: EVGN) on the TradingView platform. The content primarily shows navigation elements and general information about TradingView's offerings, but the specific financial data for EVGN is not visible.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 11:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Evogene Ltd. – NASDAQ:EVGN

This article displays the forward enterprise value to revenue for Evogene Ltd. (NASDAQ: EVGN). It is a financial data point presented by TradingView, with additional information provided by ICE Data Services and FactSet.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 03:09
Source
TradingView
TradingView Direct company coverage

Evogene Ltd Actuals & Estimates (NASDAQ:EVGN)

This article provides comprehensive financial data and analyst estimates for Evogene Ltd. (NASDAQ:EVGN), including its current stock price, historical performance, analyst forecasts, and detailed financial statements. It also covers Q3 earnings, revenue, net income, market capita

Tone
Negative 19/100
Event
Earnings
Published
25 Jun 2026 22:09
Source
TradingView
www.marketscreener.com Direct company coverage

Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization

Evogene Ltd. and Google Cloud have achieved a significant milestone in their collaboration, integrating agentic computational systems into Evogene's ChemPass AI platform. This advancement aims to accelerate small-molecule discovery and optimization by enabling early identificatio

Tone
Positive 72/100
Event
Market update
Published
25 Jun 2026 09:09
Source
www.marketscreener.com
PR Newswire Direct company coverage

Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

Evogene announced a major milestone in its collaboration with Google Cloud, integrating agentic computational systems into its ChemPass AI™ platform. This advancement aims to accelerate small-molecule discovery by enabling earlier identification of critical success criteria, ther

Tone
Positive 73/100
Event
Market update
Published
24 Jun 2026 11:39
Source
PR Newswire
Stock Titan Direct company coverage

Evogene says Google Cloud AI can screen drug candidates earlier

Evogene announced a major milestone in its collaboration with Google Cloud, integrating agentic computational systems into its ChemPass AI™ platform to enable earlier and deeper Target Product Profile (TPP) profiling for small-molecule discovery. This advancement aims to accelera

Tone
Negative 30/100
Event
Analyst action
Published
24 Jun 2026 02:10
Source
Stock Titan
TradingKey Direct company coverage

Evogene Ltd (EVGN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Evogene Ltd (EVGN), highlighting major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in their positio

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 12:40
Source
TradingKey
TradingKey Direct company coverage

Evogene Ltd (EVGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Evogene Ltd (EVGN) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts project an average price target of $2.50, with one analyst recommending a "Buy" rating. The company's expected revenue for the next quarter is $3

Tone
Positive 72/100
Event
Earnings
Published
17 Jun 2026 11:40
Source
TradingKey
Stock Titan Direct company coverage

Evogene (EVGN) showcases ChemPass AI drug and ag-chem discovery strategy

Evogene (EVGN) outlined its ChemPass AI platform, which leverages generative AI to discover and optimize small molecules for both pharmaceutical and agricultural applications. The platform's tools, PointHit, ActiveSearch, and LeadOpGPT, are designed to screen vast molecular libra

Tone
Positive 71/100
Event
Market update
Published
16 Jun 2026 11:09
Source
Stock Titan
The Globe and Mail Direct company coverage

Evogene Sets Up $2.9 Million At-the-Market Share Offering With A.G.P.

Evogene Ltd. has entered into a Sales Agreement with A.G.P./Alliance Global Partners to establish an at-the-market equity program for up to $2.93 million of its ordinary shares. This program offers the company financial flexibility but could dilute existing shareholders, with Evo

Tone
Negative 39/100
Event
Market update
Published
15 Jun 2026 07:39
Source
The Globe and Mail
PR Newswire Direct company coverage

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Evogene Ltd. will present its pharma division's advancements at the BIO International Convention from June 22-25, 2026, in San Diego. Dr. Gabi Tarcic will highlight the company's AI-driven small-molecule discovery and optimization breakthroughs, particularly focusing on how ChemP

Tone
Positive 70/100
Event
Market update
Published
12 Jun 2026 12:11
Source
PR Newswire
Investing.com Nigeria Direct company coverage

Evogene enters sales agreement for at-the-market offering of up to $2.93 million

Evogene Ltd. (NASDAQ:EVGN) has announced a sales agreement with A.G.P./Alliance Global Partners for an at-the-market (ATM) offering of up to $2.93 million in ordinary shares. This offering allows Evogene to sell shares periodically through the agent, with sales potentially occurr

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 05:11
Source
Investing.com Nigeria